Is Auvelity (dextromethorphan/bupropion) appropriate for treating agitation in an elderly patient with dementia, and what dosing and monitoring are recommended?

Auvelity is NOT appropriate for dementia-related agitation

Auvelity (dextromethorphan/bupropion) should not be used for treating agitation in elderly patients with dementia. This medication is FDA-approved only for major depressive disorder in adults, not for agitation or behavioral symptoms in dementia 1.

Why Auvelity Should Be Avoided

Lack of Approval and Evidence

• Auvelity has no FDA approval for dementia-related agitation 1
• The drug label explicitly states that clinical studies did not include patients 65 years or older, meaning safety and efficacy are unknown in this population 1
• While dextromethorphan/quinidine (a different formulation) showed some promise in a single trial for agitation 2, 3, Auvelity itself has not been studied for this indication

Safety Concerns in Elderly Dementia Patients

The 2019 AGS Beers Criteria specifically added dextromethorphan/quinidine to the "use with caution" list due to:

• Limited efficacy in behavioral symptoms of dementia without pseudobulbar affect
• Increased risk of falls
• Significant drug-drug interactions 4

Neurotoxicity Risk

The FDA label warns that neurotoxicity findings were observed in juvenile rats treated with dextromethorphan combinations, and specifically advises against breastfeeding due to potential neurotoxicity 1. This raises concerns about use in vulnerable elderly populations with dementia.

What Should Be Used Instead

First-Line: Nonpharmacological Approaches

The 2016 APA guidelines are unequivocal: nonpharmacological interventions must be reviewed before any antipsychotic use 5. These include:

• Person-centered communication
• Sensory therapy
• Environmental modifications
• Pain assessment and management

When Pharmacotherapy Is Necessary

If symptoms are severe, dangerous, or cause significant distress 5, consider these evidence-based options:

Best Safety Profile:

• Quetiapine (oral) - Only medication with significantly lower adverse events compared to haloperidol (OR 0.27) in the 2025 JAGS systematic review 6
• Start low, titrate to minimum effective dose 5

Alternative Options with Evidence:

• Risperidone - Demonstrated efficacy but requires monitoring for cerebrovascular and extrapyramidal risks 3
• Citalopram - Consider when safety is prioritized over efficacy 7

Avoid:

• Benzodiazepines, especially midazolam - 53% adverse event rate, 5.25-fold increased risk versus haloperidol 6
• Haloperidol - Appeared less efficacious than nearly all comparators 3

Critical Monitoring Requirements

If antipsychotics are used:

• Assess response with quantitative measures (e.g., CMAI, NPI-A) 5
• If no response after 4 weeks at adequate dose, taper and discontinue 5
• Adverse events occur in 16.8% of older adults receiving antipsychotics or anxiolytics for agitation 6
• Monitor for respiratory depression, dysrhythmia, hypotension, falls, and delirium 6

Common Pitfalls to Avoid

1. Using Auvelity off-label - No evidence base and unknown safety in elderly
2. Skipping nonpharmacological interventions - These must be attempted first unless emergency situation
3. Using parenteral routes - IV/IM administration increases adverse event risk compared to oral 6
4. Continuing indefinitely - Reassess need for tapering once symptoms stabilize 5
5. Ignoring dose-response relationships - Higher doses of lorazepam showed increased adverse events 6